Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
Gilead Sciences, Kite, and oNKo-innate announced that the companies entered into a three-year cancer immunotherapy research collaboration to support the discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
The immuno-oncology therapy CAR-T utilizes specific types of immune cells, T-cells, which are drawn from the cancer patient, supercharged and infused back into the patient. Now, The University of Texas MD Anderson Cancer Center has developed a slightly different approach using a different type of immune cell called Natural Killer (NK) cells.
Dragonfly Therapeutics and AbbVie forged a multi-target research collaboration to advance new treatment options for autoimmune and oncology indications.
Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.
Janssen Biotech informed Aduro Biotech that the Johnson & Johnson company was terminating a research and license deal related to Aduro’s Listeria treatment for cancers.
Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck, which will license exclusive rights to Dragonfly’s TriNKET technology platform for a number of solid-tumor programs.